SMA treatment risdiplam

EMA grants PRIME designation for SMA treatment risdiplam

Roche announces that its SMA treatment risdiplam is granted PRIME designation by the European Medicines Agency (EMA).  Roche has announced that the European Medicines Agency...
first cohort of medica writers from Ashfield's Allegro

medac’s TRECONDI® (treosulfan) gets positive CHMP opinion

medac Gesellschaft für klinische Spezialpräparate mbH has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Novartis and the University of Oxford’s Big Data Institute to improve drug development

New lab space for life science at Alderley Park

Plans to create more high specification space for small bioscience businesses in the North of England progress today as Bruntwood SciTech announces £10m investment...
Outdated mental health commissioning contracts are failing services

Novartis receives European Commission approval for self-administration of Xolair® across all indications

Novartis has announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA)...
NICE have released draft guidance for patisiran for adults living with hATTR amyloidosis who have stage 1 or 2 polyneuropathy.

NICE releases draft guidance for patisiran for hATTR amyloidosis

NICE have released draft guidance for patisiran for adults living with hATTR amyloidosis who have stage 1 or 2 polyneuropathy. As part of a Highly-Specialised...
A woman undergoing a breast appointment to show Perjeta for Scottish breast cancer patients

Access to Perjeta for Scottish breast cancer patients

Perjeta has been approved for Scottish breast cancer patients by the Scottish Medicines Consortium (SMC). SMC has recommended that Perjeta® (pertuzumab) should be made available...
Man taking stars from the EU flag to demonstrate the brexit life sciences brain drain

The Brexit Life Sciences Brain Drain: 14% of life sciences professionals could leave UK

The Brexit life sciences brain drain could happen as a new report finds that 14% of life sciences professionals in the UK could be...
New partnership for health innovation

AstraZeneca & Cancer Research UK launch Functional Genomics Centre

Cancer Research UK and AstraZeneca will open a centre dedicated to functional genomics in the discovery and development of new cancer drugs. The Centre will...
100,000 Genomes Project

100,000 Genomes Project achieves sequencing goal

The 100,000 Genomes Project has achieved its goal of sequencing 100,000 whole genomes from NHS patients. The project, which began in 2012, was established with...
IQVIA sector deal

IQVIA welcomes Trade Minister to UK HQ

IQVIA has welcomed Minister for Trade and Export Promotion, Baroness Rona Fairhead, to its UK HQ, following £44m Sector Deal announcements. The visit highlighted the...

Latest articles

IMBRUVICA® misses primary endpoint in pancreatic cancer trial

IMBRUVICA® misses primary endpoint in pancreatic cancer trial

AbbVie have released an update on the RESOLVE trial of IMBRUVICA® in combination with chemotherapy agents in metastatic pancreatic cancer.  AbbVie, a research-based global biopharmaceutical company,...
Star Europe reports positive client and candidate feedback.

Star Europe’s Amsterdam office off to positive start

Star Europe has reported good feedback in the Netherlands since opening its Amsterdam office in November. Supported by established resources and infrastructure, the team at...
ORKAMBI® for cystic fibrosis

EC approves Vertex’s ORKAMBI® for cystic fibrosis patients

Vertex Pharmaceuticals announces that the European Commission has granted approval of the label extension for ORKAMBI® for cystic fibrosis patients.  The European Commission has granted approval...